Feature selection is one of the most important challenges in machine learning and data science. This process is usually performed in the data preprocessing phase, where the data is transformed to a proper format for further operations by machine learning algorithm. Many real-world datasets are highly dimensional with many irrelevant, even redundant features. These kinds of features do not improve classification accuracy and can even shrink down performance of a classifier. The goal of feature selection is to find optimal (or sub-optimal) subset of features that contain relevant information about the dataset from which machine learning algorithms can derive useful conclusions. In this manuscript, a novel version of firefly algorithm (FA) is proposed and adapted for feature selection challenge. Proposed method significantly improves performance of the basic FA, and also outperforms other state-of-the-art metaheuristics for both, benchmark bound-constrained and practical feature selection tasks. Method was first validated on standard unconstrained benchmarks and later it was applied for feature selection by using 21 standard University of California, Irvine (UCL) datasets. Moreover, presented approach was also tested for relatively novel COVID-19 dataset for predicting patients health, and one microcontroller microarray dataset. Results obtained in all practical simulations attest robustness and efficiency of proposed algorithm in terms of convergence, solutions' quality and classification accuracy. More precisely, the proposed approach obtained the best classification accuracy on 13 out of 21 total datasets, significantly outperforming other competitor methods.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901218 | PMC |
http://dx.doi.org/10.1016/j.micpro.2023.104778 | DOI Listing |
Alzheimers Dement
December 2024
Université de Lille, Lille, Hauts-de-France, France.
Background: Tau proteins aggregate in a number of neurodegenerative disorders known as tauopathies. Various studies have highlighted the role of microtubule-binding domains in the intracellular aggregation of Tau protein.
Method: Using a library of synthetic VHHs humanized in collaboration with Hybrigenics, we have developed a number of anti-tau VHHs.
Alzheimers Dement
December 2024
Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
Background: Some types of cancer have been associated with reduced risk of clinical dementia diagnosis. Whether cancer history may be associated with neuropathological features of neurodegeneration or cerebrovascular disease is not well understood. We investigated the relation between cancer diagnosis and brain pathology in a sample of community-based research volunteers enrolled in an Alzheimer's Disease Research Center (ADRC) cohort.
View Article and Find Full Text PDFBackground: Small, soluble oligomers, rather than mature fibrils, are the major neurotoxic agents in Alzheimer's disease (AD). In the last few years, Aprile and co-workers designed and purified a single-domain antibody (sdAb), called DesAb-O, with high specificity for Aβ oligomeric conformers. Recently, Cascella and co-workers showed that DesAb-O can selectively detect synthetic Aβ oligomers both in vitro and in cultured cells, neutralizing their associated neuronal dysfunction.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Korea Institute of Science and Technology, Seoul, Korea, Republic of (South).
Background: Elevation of cerebrospinal fluid (CSF) tau is a feature of Alzheimer's disease (AD) and is being explored as a biomarker of AD and other tauopathies. The aim of this study was to elucidate the in vivo effects of DA-7503, a potent and selective tau aggregation inhibitor, and its pharmacodynamics on CSF tau in transgenic mouse models of Alzheimer's disease and primary tauopathies.
Method: TauP301L-BiFC mice expressing full-length human tau with the P301L mutation were orally administrated with DA-7503 for 1 month.
Alzheimer's Disease (AD) is characterized by the amyloid plaques in patient brain. The plaques are formed by β-amyloid peptides (Aβs) that derive from the cleavage by γ-secretase. Over 300 AD pathogenic mutations have been identified in presenilin1/2 (PS1/PS2), the catalytic subunit of γ-secretase.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!